Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Consolidated Net Income (2016 - 2023)

Historic Consolidated Net Income for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $58.9 million.

  • RedHill Biopharma's Consolidated Net Income rose 79179.66% to $58.9 million in Q2 2023 from the same period last year, while for Dec 2024 it was $58.9 million, marking a year-over-year increase of 41816.51%. This contributed to the annual value of -$14613.0 billion for FY2024, which is 6110142821.12% down from last year.
  • RedHill Biopharma's Consolidated Net Income amounted to $58.9 million in Q2 2023, which was up 79179.66% from -$7.9 million recorded in Q1 2023.
  • RedHill Biopharma's 5-year Consolidated Net Income high stood at $58.9 million for Q2 2023, and its period low was -$145.2 million during Q4 2021.
  • Over the past 5 years, RedHill Biopharma's median Consolidated Net Income value was $11.1 million (recorded in 2019), while the average stood at -$1.3 million.
  • As far as peak fluctuations go, RedHill Biopharma's Consolidated Net Income crashed by 106284.39% in 2021, and later soared by 79179.66% in 2023.
  • Over the past 5 years, RedHill Biopharma's Consolidated Net Income (Quarter) stood at $11.8 million in 2019, then increased by 27.44% to $15.1 million in 2020, then crashed by 1062.84% to -$145.2 million in 2021, then soared by 52.14% to -$69.5 million in 2022, then soared by 184.75% to $58.9 million in 2023.
  • Its Consolidated Net Income stands at $58.9 million for Q2 2023, versus -$7.9 million for Q1 2023 and -$69.5 million for Q4 2022.